Review



fc silent control igg mab mopc21  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Bio X Cell fc silent control igg mab mopc21
    Fc Silent Control Igg Mab Mopc21, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 100 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pmc11750626-704-17-52?v=Bio+X+Cell
    Average 96 stars, based on 100 article reviews
    fc silent control igg mab mopc21 - by Bioz Stars, 2026-08
    96/100 stars

    Images



    Similar Products

    93
    Sino Biological anti cd47 monoclonal antibody
    Anti Cd47 Monoclonal Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pmc11754784__41467_2025_56219_MOESM2_ESM-47-1-4?v=Sino+Biological
    Average 93 stars, based on 1 article reviews
    anti cd47 monoclonal antibody - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    93
    R&D Systems anti cd47 mab
    Fig. 4 <t>CD47</t> blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.
    Anti Cd47 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pm40523887-91-15-29?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    anti cd47 mab - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology anti-human cd47 mouse mab sc-12730
    Fig. 4 <t>CD47</t> blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.
    Anti Human Cd47 Mouse Mab Sc 12730, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pm40379682-469-0-9?v=Santa+Cruz+Biotechnology
    Average 90 stars, based on 1 article reviews
    anti-human cd47 mouse mab sc-12730 - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    96
    Bio X Cell fc silent control igg mab mopc21
    Fig. 4 <t>CD47</t> blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.
    Fc Silent Control Igg Mab Mopc21, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pmc11750626-704-17-52?v=Bio+X+Cell
    Average 96 stars, based on 1 article reviews
    fc silent control igg mab mopc21 - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    93
    R&D Systems anti mcd47 mab af1866
    Fig. 4 <t>CD47</t> blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.
    Anti Mcd47 Mab Af1866, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pmc11750626-505-16-19?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    anti mcd47 mab af1866 - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    96
    Bio X Cell anti cd47 mab miap301
    Fig. 4 <t>CD47</t> blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.
    Anti Cd47 Mab Miap301, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+cd47+mab/pmc11750626-704-22-52?v=Bio+X+Cell
    Average 96 stars, based on 1 article reviews
    anti cd47 mab miap301 - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 4 CD47 blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.

    Journal: Cell death & disease

    Article Title: SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1 + myeloid cells in hepatocellular carcinoma.

    doi: 10.1038/s41419-025-07779-7

    Figure Lengend Snippet: Fig. 4 CD47 blockade therapy suppressed tumor progression in the PDX model. A–C A PDX tumor model was constructed using NSG mice using human HCC tissues. Schematic diagram showing the construction of a PDX tumor model and huPBMC injection through the tail vein. Mice (n = 6 for each group) were treated with anti-CD47 antagonist TTI-621 (8 mg/kg, three times a week for 3–4 weeks, i.p.) or vehicle (A). The tumor images (scale bar, 1 cm) (B), tumor weight (C) in the PDX tumor model using HCC tissues from patient 1. D–G The survival and tumor sizes of the tumor-bearing mice were recorded from patients 1–4. H, I mIF analysis of the tumor tissues in PDX model was used to detect the TIMs (CD11b), PD-L1, CD8+ T cells, and cytotoxic function (GZMB). Scale bar, 50 μm. J, K Western blot and qRT-PCR analysis were used to detect the PD-L1 expression in TIMs of tumor tissues in the PDX model. TIMs were obtained through magnetic bead sorting. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.

    Article Snippet: Myeloid cells with or without SIRPA overexpression were treated with anti-SIRPα mAb (5 μg/ml) or anti-CD47 mAb (10 μg/ml) compared with the control, followed by incubation with mCD47-Fc (Cat#1866-CD-050, R&D Systems) for 12 h. Cells were collected for analysis after cocultivation.

    Techniques: Construct, Injection, Western Blot, Quantitative RT-PCR, Expressing

    Fig. 6 SIRPα/CD47 axis promoted migration, PD-L1 expression of macrophages and HCC growth via upregulating PI3K/AKT signaling. A Schematic of the in vitro coculture experiments with PMA-treated THP-1 cells cocultured with Hepa1–6 or LPC-H12 cells to mimic liver cancer microenvironment treated with anti-CD47 mAb (10 μg/ml) or not. Macrophages were incubated with mCD47-Fc for 12 h before analysis. B Western blot analysis was used to detect the expression of indicated proteins in macrophages. C, D Transwell assay was used to detect the migration of macrophages towards the supernatants of the indicated groups. Scale bar, 100 μm. E Orthotopic HCC model using Hepa1–6 was established. Wild- type C57BL/6 mice (n = 6 for each group) were treated with anti-SIRPα mAb (100 μg/mouse, i.p.) and/or GSK690693 (30 mg/kg/day, i.p.) compared with the control group. Representative livers in each group were photographed at the endpoint (Scale bar, 1 cm). F, G Statistical analysis of tumor volume and tumor weight of the mice. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.

    Journal: Cell death & disease

    Article Title: SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1 + myeloid cells in hepatocellular carcinoma.

    doi: 10.1038/s41419-025-07779-7

    Figure Lengend Snippet: Fig. 6 SIRPα/CD47 axis promoted migration, PD-L1 expression of macrophages and HCC growth via upregulating PI3K/AKT signaling. A Schematic of the in vitro coculture experiments with PMA-treated THP-1 cells cocultured with Hepa1–6 or LPC-H12 cells to mimic liver cancer microenvironment treated with anti-CD47 mAb (10 μg/ml) or not. Macrophages were incubated with mCD47-Fc for 12 h before analysis. B Western blot analysis was used to detect the expression of indicated proteins in macrophages. C, D Transwell assay was used to detect the migration of macrophages towards the supernatants of the indicated groups. Scale bar, 100 μm. E Orthotopic HCC model using Hepa1–6 was established. Wild- type C57BL/6 mice (n = 6 for each group) were treated with anti-SIRPα mAb (100 μg/mouse, i.p.) and/or GSK690693 (30 mg/kg/day, i.p.) compared with the control group. Representative livers in each group were photographed at the endpoint (Scale bar, 1 cm). F, G Statistical analysis of tumor volume and tumor weight of the mice. All data presented are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.

    Article Snippet: Myeloid cells with or without SIRPA overexpression were treated with anti-SIRPα mAb (5 μg/ml) or anti-CD47 mAb (10 μg/ml) compared with the control, followed by incubation with mCD47-Fc (Cat#1866-CD-050, R&D Systems) for 12 h. Cells were collected for analysis after cocultivation.

    Techniques: Migration, Expressing, In Vitro, Incubation, Western Blot, Transwell Assay, Control